首页> 外文期刊>Substance Abuse Treatment, Prevention, and Policy >Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey
【24h】

Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey

机译:加拿大不列颠哥伦比亚省美沙酮制剂变更的患者观点:省级调查的结果

获取原文
           

摘要

In British Columbia, Canada, methadone maintenance treatment formulation transitioned from the oral liquid compound Tang?-flavoured methadone to the ten-times more concentrated cherry-flavoured Methadose? in February 2014. We quantitatively describe perceptions and reported consequences among a sample of patients on methadone maintenance treatment following this transition. A province-wide survey was used. Bivariable analyses utilized independent samples t-tests, Phi associations, and Chi-square tests. Multivariable logistic regression analyses evaluated factors related to dependent variables – namely, increases in dose, pain, dope sickness, and the need to supplement with additional opioids. Four hundred five methadone maintenance treatment patients from fifty harm reduction sites across British Columbia reported transitioning to Methadose? in February 2014. The majority (n?=?258; 73.1?%) heard about the formulation change from their methadone provider or pharmacist. Adjusted models show worse taste was positively associated with reporting an increasing dose (OR?=?2.46; CI:1.31–4.61), feeling more dope sick (OR?=?3.39; CI:1.88–6.12), and worsening pain (OR?=?4.65; CI:2.45–8.80). Feeling more dope sick was positively associated with dose increase (OR?=?2.24; CI:1.37–3.66), and supplementing with opioids (OR?=?8.81; CI:5.16–15.05). Methadone maintenance treatment policy changes in British Columbia affect a structurally vulnerable population who may be less able to cope with transitions and loss of autonomy. There may be a psychosocial component contributing to the perception of Methadose? tasting worse, and increased dope sickness, pain, and dose. Our study shows the pronounced negative impacts medication changes can have on patients without informed, coordinated efforts. We stress the need to engage all stakeholders allowing for communication about the reasons, risks and consequences of medication policy changes and provision of additional psychosocial support.
机译:在加拿大的不列颠哥伦比亚省,美沙酮维持治疗制剂已从口服液体复合物Tang?风味的美沙酮过渡到浓缩了10倍的樱桃味美沙酮? 2014年2月。我们定量描述了这种转变后美沙酮维持治疗的患者样本中的感知并报告了后果。使用了全省范围的调查。双变量分析利用独立样本t检验,Phi关联和卡方检验。多变量logistic回归分析评估了与因变量相关的因素,即,剂量增加,疼痛,兴奋剂病和需要补充其他阿片类药物。来自不列颠哥伦比亚省五十个减害地点的四百零五美沙酮维持治疗患者报告已转用美沙酮?在2014年2月。大多数(n?=?258; 73.1%)的患者从他们的美沙酮供应商或药剂师那里听说过配方变更。调整后的模型显示,较差的味道与报告剂量增加呈正相关(OR?=?2.46; CI:1.31–4.61),感觉更多的涂料不适(OR?=?3.39; CI:1.88–6.12)和疼痛加重(OR ?=?4.65; CI:2.45-8.80)。感到更多的涂料患病与剂量增加呈正相关(OR?=?2.24; CI:1.37–3.66),并补充阿片类药物(OR?=?8.81; CI:5.16-15-1.05)。不列颠哥伦比亚省的美沙酮维持治疗政策变化影响了结构脆弱的人群,这些人群可能难以应对过渡和丧失自治权。可能有心理社会因素有助于美沙酮的感知?品尝更糟,并增加了涂料的疾病,疼痛和剂量。我们的研究表明,如果没有知情的,不协调的努力,药物变化可能会对患者产生明显的负面影响。我们强调需要让所有利益相关者参与进来,以便就药物政策变更的原因,风险和后果以及提供额外的社会心理支持进行交流。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号